Clinical Trial Update: Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma [Phase 4]

View source ↗

Summary

Phase 4 study assessing the safety and tolerability of omalizumab in patients with mild to moderate asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 4 | Status: COMPLETED